# The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects

> **NCT03582280** · PHASE1 · TERMINATED · sponsor: **Amorphical Ltd.** · enrollment: 11 (actual)

## Conditions studied

- Oncology

## Interventions

- **DRUG:** Amorphous Calcium Carbonate (ACC) - Amor

## Key facts

- **NCT ID:** NCT03582280
- **Lead sponsor:** Amorphical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-18
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-10-31
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03582280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03582280, "The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03582280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*